Cytarabine + Daunorubicin Liposomal 44mg/ 100 ml Suppliers & Bulk Manufacturers

Available Forms: Liposomal injectable

Available Strengths: 44mg/ 100 ml

Reference Brands: Vyxeos

Category: Liposomal Drug Delivery

Cytarabine + Daunorubicin liposomal (Vyxeos) delivers targeted chemotherapy by encapsulating drugs in liposomes, increasing tumor cell uptake. It inhibits DNA synthesis and promotes cell death. Benefits include enhanced efficacy, reduced toxicity, and improved survival outcomes for acute myeloid leukemia (AML) patients, supporting personalized cancer therapy.

Product Description:

Cytarabine + Daunorubicin liposomal (Vyxeos) is regulated in the US and EU, supported by dossiers demonstrating safety, efficacy, and manufacturing quality in compliance with GMP and MDR standards. In the US, FDA approval involved extensive clinical validation and safety assessments. In the EU, CE marking certifies conformity with MDR regulations. These formulations undergo validation, stability testing, and audits, with comprehensive documentation including safety profiles, clinical trial data, and manufacturing practices. For licensing procedures, approved dossiers, and latest regulatory updates, visit Pharmatradz. Ensuring compliance guarantees access to high-quality liposomal chemotherapies for AML treatment, supporting effective, targeted cancer therapy worldwide.